New Antibody Biomarkers May Improve Early Detection of Lyme Disease, Predict Persistent Symptoms
Researchers have identified anti-lipid antibodies that may serve as early biomarkers for Lyme disease and help predict persistent post-treatment symptoms. These findings could lead to more accurate diagnostic tests compared to current methods that rely on protein-based antibodies.
Why it matters
Improved diagnostic accuracy for Lyme disease could significantly impact patient outcomes by enabling earlier treatment and providing clarity for those suffering from chronic post-treatment symptoms.
Researchers have identified a distinct set of anti-lipid antibodies that could improve the early diagnosis of Lyme disease while also helping distinguish patients who develop persistent symptoms after treatment from those who recover fully.
The report is a neutral summary of scientific research findings.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in